Abstract
Evaluation of: Newhouse P, Kellar K, Aisen P et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 78(2), 91–101 (2012).There have been several drug trials in recent years investigating the efficacy of commonly used Alzheimer’s disease therapies for symptoms of mild cognitive impairment (MCI). However, there are no US FDA-approved pharmacological treatments for MCI. As the incidence rates of MCI are considerable, it is clear that better treatments for MCI need to be developed. The reviewed paper presents new data on a pilot clinical trial which shows that transdermal nicotine treatment for 6 months improved cognitive performance in subjects with amnestic MCI. Further studies will possibly bring us wider usage of nicotine for individuals with cognitive dysfunction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
